Atea Pharmaceuticals, Inc.
AVIR Healthcare Biotechnology
In the quarter to June 2026, EPS grew 6.82% and free cash flow grew 85.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow AVIR
Atea Pharmaceuticals, Inc. (AVIR) EV/Sales
As of 16 October 2026, Atea Pharmaceuticals, Inc. (AVIR) trades at a EV/Sales of 0.4×. Over the past ten years it has ranged from −1.1× (March 2023) to 13.7× (October 2021); the current reading is higher than 90% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2021 | −0.1× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2021 | −0.1× | — |
| Sep 2021 | 9.9× | — |
| Jun 2021 | 0.0× | — |
| Mar 2021 | 0.0× | — |
| 1 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TTRX Turn Therapeutics Inc. compare | n/m |
| KYTX Kyverna Therapeutics, Inc. compare | n/m |
| RZLT Rezolute, Inc. compare | n/m |
| GALT Galectin Therapeutics Inc. compare | n/m |
| AVIR Atea Pharmaceuticals, Inc. | 0.4× |
| EDIT Editas Medicine, Inc. compare | 2.2× |
| CCCC C4 Therapeutics, Inc. compare | 3.6× |
| FENC Adherex Technologies Inc. compare | 5.4× |
| OBIO Orchestra BioMed Holdings, Inc. compare | 8.5× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)